Takeda acquires Inviragen and their DENVax vaccine

Japanese firm Takeda has announced that it will acquire Inviragen for an upfront payment of US$35 million, and future payments of up to $215 million. With the acquisition also comes Inviragen's advanced vaccine candidate against dengue, DENVax, which recently moved into the second stage of Phase II trials. "The acquisition of Inviragen supports Takeda's overall research and development programs, long-term …

New dengue vaccine shows promise: DENVax moves into second stage of phase 2

Inviragen have announced that the dengue vaccine DENVax has shown promise in trials and has advanced into the second stage of an ongoing phase II, randomized, double-blind, placebo-controlled trial being conducted in Puerto Rico, Colombia, Thailand and Singapore. "The completion of the first stage of this Phase 2 study is an important milestone for Inviragen, as it represents the first …